Biogeneric race in Europe heats up

Swiss biopharmaceutical firm Biopartners has got the thumbs up from the European Commission for its biosimilar drug Valtropin, making it only the second biogeneric drug to have been approved in Europe after Sandoz’s Omnitrope received marketing authorisation last month. Both drugs are based on somatropin, a growth hormone produced by recombinant DNA technology, and are set to compete with other products on the European market sold by Novo Nordisk, Eli Lilly, Genentech and Serono. "Source":[ http://www.in-pharmatechnologist.com/news/ng.asp?n=67646-biopartners-valtropin-biogenerics-omnitrope-sandoz]

---